rabeprazole has been researched along with Gastritis in 35 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Gastritis: Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy of rabeprazole and hydrotalcite in patients with bile reflux gastritis after cholecystectomy." | 9.14 | Rabeprazole combined with hydrotalcite is effective for patients with bile reflux gastritis after cholecystectomy. ( Chen, H; Chen, X; Cui, Y; Gao, Y; Ge, Z; Li, X, 2010) |
| "Both sucralfate and rabeprazole therapies are effective treatment options in the patients with alkaline gastritis when compared with observation." | 9.10 | Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment. ( Cammarota, G; Candelli, M; Cremonini, F; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Nista, EC; Santarelli, L, 2003) |
| "Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis." | 9.08 | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. ( Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998) |
| " Very few cases of adverse side-effects related to these drugs, when given individually, have been reported; serious side-effects of clarithromycin in combination with rabeprazole have never been reported." | 5.39 | Dissociative disorder induced by clarithromycin combined with rabeprazole in a patient with gastritis. ( Feng, Z; Hu, S; Huang, J; Xu, Y; Zhang, M, 2013) |
| "To assess the efficacy of rabeprazole and hydrotalcite in patients with bile reflux gastritis after cholecystectomy." | 5.14 | Rabeprazole combined with hydrotalcite is effective for patients with bile reflux gastritis after cholecystectomy. ( Chen, H; Chen, X; Cui, Y; Gao, Y; Ge, Z; Li, X, 2010) |
| "Two hundred and forty-three patients received rabeprazole (20 mg or 10 mg) or omeprazole (20 mg) once daily for up to 5 years, for gastro-oesophageal reflux disease and 51% completed the whole 5 year period." | 5.11 | Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. ( Fiocca, R; Jacobs, A; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2005) |
| " pylori-positive gastritis or peptic ulcers were randomly assigned to receive 30 mg lansoprazole twice daily (LAC group), 10 mg rabeprazole twice daily (RAC20 group), or 20 mg rabeprazole twice daily (RAC40 group), with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week." | 5.10 | Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. ( Aoyama, N; Kasuga, M; Kita, T; Kuroda, K; Maekawa, S; Miki, I; Okumura, K; Sakaeda, T; Sakai, T; Shirasaka, D; Tamura, T; Wambura, CM, 2003) |
| "Both sucralfate and rabeprazole therapies are effective treatment options in the patients with alkaline gastritis when compared with observation." | 5.10 | Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment. ( Cammarota, G; Candelli, M; Cremonini, F; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Nista, EC; Santarelli, L, 2003) |
| "A total of 170 Helicobacter pylori-positive patients with chronic gastritis were randomized to receive one of the following Helicobacter pylori eradication regimens; OAC (omeprazole 20 mg bd, amoxycillin 750 mg bd and clarithromycin 400 mg bd for 1 week) and RAC (rabeprazole 20 mg bd, amoxycillin 750 mg bd and clarithromycin 400 mg bd for 1 week)." | 5.09 | Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. ( Azuma, T; Dojo, M; Kuriyama, M; Muramatsu, A; Ohtani, M; Saito, T, 2001) |
| "Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis." | 5.08 | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. ( Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998) |
| " Examination of eradication rates according to CAM dosage revealed an eradication rate of 65." | 1.40 | Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). ( Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Masaoaka, T; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A, 2014) |
| " Very few cases of adverse side-effects related to these drugs, when given individually, have been reported; serious side-effects of clarithromycin in combination with rabeprazole have never been reported." | 1.39 | Dissociative disorder induced by clarithromycin combined with rabeprazole in a patient with gastritis. ( Feng, Z; Hu, S; Huang, J; Xu, Y; Zhang, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.86) | 18.2507 |
| 2000's | 17 (48.57) | 29.6817 |
| 2010's | 13 (37.14) | 24.3611 |
| 2020's | 4 (11.43) | 2.80 |
| Authors | Studies |
|---|---|
| Myint, NPST | 1 |
| Zaw, TT | 1 |
| Sain, K | 1 |
| Waiyan, S | 1 |
| Danta, M | 1 |
| Cooper, D | 1 |
| Aung, NM | 1 |
| Kyi, MM | 1 |
| Hanson, J | 1 |
| Kono, Y | 1 |
| Kusumoto, C | 1 |
| Kiguchi, T | 1 |
| Okada, H | 1 |
| Teng, G | 1 |
| Liu, Y | 1 |
| Wu, T | 1 |
| Wang, W | 1 |
| Wang, H | 1 |
| Hu, F | 1 |
| Tang, Y | 1 |
| Tang, G | 1 |
| Pan, L | 1 |
| Zhu, H | 1 |
| Zhou, S | 1 |
| Wei, Z | 1 |
| Kawasaki, K | 1 |
| Kurahara, K | 1 |
| Oshiro, Y | 1 |
| Ohtsu, K | 1 |
| Nakamura, S | 1 |
| Fuchigami, T | 1 |
| Matsumoto, T | 1 |
| Sue, S | 1 |
| Shibata, W | 1 |
| Sasaki, T | 1 |
| Kaneko, H | 1 |
| Irie, K | 1 |
| Kondo, M | 1 |
| Maeda, S | 1 |
| Feng, Z | 1 |
| Huang, J | 1 |
| Xu, Y | 1 |
| Zhang, M | 1 |
| Hu, S | 1 |
| Furuta, T | 1 |
| Sugimoto, M | 1 |
| Kodaira, C | 1 |
| Nishino, M | 1 |
| Yamade, M | 1 |
| Uotani, T | 1 |
| Sahara, S | 1 |
| Ichikawa, H | 1 |
| Yamada, T | 1 |
| Osawa, S | 1 |
| Sugimoto, K | 1 |
| Watanabe, H | 1 |
| Umemura, K | 1 |
| Oh, DH | 1 |
| Lee, DH | 1 |
| Kang, KK | 1 |
| Park, YS | 1 |
| Shin, CM | 1 |
| Kim, N | 1 |
| Yoon, H | 1 |
| Hwang, JH | 1 |
| Jeoung, SH | 1 |
| Kim, JW | 1 |
| Jang, ES | 1 |
| Jung, HC | 1 |
| Kawai, T | 1 |
| Takahashi, S | 1 |
| Suzuki, H | 2 |
| Sasaki, H | 1 |
| Nagahara, A | 1 |
| Asaoka, D | 1 |
| Matsuhisa, T | 1 |
| Masaoaka, T | 1 |
| Nishizawa, T | 1 |
| Suzuki, M | 2 |
| Ito, M | 1 |
| Kurihara, N | 1 |
| Omata, F | 1 |
| Mizuno, S | 1 |
| Torii, A | 1 |
| Kawakami, K | 1 |
| Ohkusa, T | 1 |
| Tokunaga, K | 1 |
| Mine, T | 1 |
| Sakaki, N | 1 |
| Lee, HJ | 1 |
| Kim, JI | 1 |
| Lee, JS | 1 |
| Jun, EJ | 1 |
| Oh, JH | 1 |
| Cheung, DY | 1 |
| Chung, WC | 1 |
| Kim, BW | 1 |
| Kim, SS | 1 |
| Ben Chaabane, N | 1 |
| Al-Adhba, HS | 1 |
| Shiratori, S | 1 |
| Mabe, K | 1 |
| Yoshii, S | 1 |
| Takakuwa, Y | 1 |
| Sato, M | 1 |
| Nakamura, M | 1 |
| Kudo, T | 1 |
| Kato, M | 1 |
| Asaka, M | 1 |
| Sakamoto, N | 1 |
| de Artaza Varasa, T | 1 |
| Valle Muñoz, J | 1 |
| Pérez-Grueso, MJ | 1 |
| García Vela, A | 1 |
| Martín Escobedo, R | 1 |
| Rodríguez Merlo, R | 1 |
| Cuena Boy, R | 1 |
| Carrobles Jiménez, JM | 1 |
| Chen, H | 1 |
| Li, X | 1 |
| Ge, Z | 1 |
| Gao, Y | 1 |
| Chen, X | 2 |
| Cui, Y | 1 |
| Mansour, NM | 1 |
| Hashash, JG | 1 |
| El-Halabi, M | 1 |
| Ghaith, O | 1 |
| Maasri, K | 1 |
| Sukkarieh, I | 1 |
| Malli, A | 1 |
| Sharara, AI | 1 |
| Choi, HS | 1 |
| Chun, HJ | 1 |
| Park, SH | 1 |
| Keum, B | 1 |
| Seo, YS | 1 |
| Kim, YS | 1 |
| Jeen, YT | 1 |
| Um, SH | 1 |
| Lee, HS | 1 |
| Kim, CD | 1 |
| Ryu, HS | 1 |
| Zhao, S | 1 |
| Sha, H | 1 |
| Li, ZY | 1 |
| Ren, CS | 1 |
| Murakami, K | 3 |
| Sato, R | 3 |
| Okimoto, T | 3 |
| Nasu, M | 2 |
| Fujioka, T | 3 |
| Kodama, M | 3 |
| Kagawa, J | 1 |
| Sato, S | 2 |
| Abe, H | 1 |
| Arita, T | 2 |
| Miki, I | 1 |
| Aoyama, N | 1 |
| Sakai, T | 1 |
| Shirasaka, D | 1 |
| Wambura, CM | 1 |
| Maekawa, S | 1 |
| Kuroda, K | 1 |
| Tamura, T | 1 |
| Kita, T | 1 |
| Sakaeda, T | 1 |
| Okumura, K | 1 |
| Kasuga, M | 1 |
| Santarelli, L | 1 |
| Gabrielli, M | 1 |
| Candelli, M | 1 |
| Cremonini, F | 1 |
| Nista, EC | 1 |
| Cammarota, G | 1 |
| Gasbarrini, G | 1 |
| Gasbarrini, A | 1 |
| Hata, M | 1 |
| Shiono, M | 1 |
| Sekino, H | 1 |
| Furukawa, H | 1 |
| Sezai, A | 1 |
| Iida, M | 1 |
| Yoshitake, I | 1 |
| Hattori, T | 1 |
| Wakui, S | 1 |
| Soeda, M | 1 |
| Taoka, M | 1 |
| Negishi, N | 1 |
| Sezai, Y | 1 |
| Rindi, G | 1 |
| Fiocca, R | 1 |
| Morocutti, A | 1 |
| Jacobs, A | 1 |
| Miller, N | 1 |
| Thjodleifsson, B | 1 |
| Wang, F | 1 |
| Wang, XY | 1 |
| Jia, Y | 1 |
| Shen, SR | 1 |
| Xu, CX | 1 |
| Tang, WL | 1 |
| Liu, SJ | 1 |
| Watanabe, K | 2 |
| Abe, T | 1 |
| Onoda, N | 1 |
| Katsuragi, K | 1 |
| Sawada, T | 1 |
| Maeda, K | 1 |
| Mino, A | 1 |
| Ohira, M | 1 |
| Ishikawa, T | 1 |
| Wakasa, K | 1 |
| Hirakawa, K | 1 |
| Beyenburg, S | 1 |
| Schönegger, K | 1 |
| Serebrova, SIu | 1 |
| Livzan, MA | 1 |
| Kononov, AV | 1 |
| Mozgovoĭ, SI | 1 |
| Stack, WA | 1 |
| Knifton, A | 1 |
| Thirlwell, D | 1 |
| Cockayne, A | 1 |
| Jenkins, D | 1 |
| Hawkey, CJ | 1 |
| Atherton, JC | 1 |
| Ohara, T | 1 |
| Goshi, S | 1 |
| Taneike, I | 1 |
| Tamura, Y | 1 |
| Zhang, HM | 1 |
| Yamamoto, T | 1 |
| Dojo, M | 1 |
| Azuma, T | 1 |
| Saito, T | 1 |
| Ohtani, M | 1 |
| Muramatsu, A | 1 |
| Kuriyama, M | 1 |
| Zullo, A | 1 |
| Hassan, C | 1 |
| Lorenzetti, R | 1 |
| Morini, S | 1 |
| Kitahora, T | 1 |
| Miyazawa, M | 1 |
| Nagahashi, S | 1 |
| Suzuki, K | 1 |
| Ishii, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication[NCT02547038] | 352 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori[NCT01922765] | Phase 4 | 540 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (Number of Participants With Complete Eradication of Helicobacter Pylori) (NCT02547038)
Timeframe: sixth week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 169 |
| (Panto+Amox+Clar+Metr)+(Panto+Amox) | 170 |
2 reviews available for rabeprazole and Gastritis
| Article | Year |
|---|---|
Gastrointestinal: Rapid emergence of double-expressor lymphoma after Helicobacter pylori eradication therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Endoscopy, Digestive System; Follow-Up Studies; Gastric Mu | 2021 |
A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Chronic Disease; | 2011 |
22 trials available for rabeprazole and Gastritis
| Article | Year |
|---|---|
Sequential Helicobacter pylori eradication therapy in Myanmar; a randomized clinical trial of efficacy and tolerability.
Topics: Amoxicillin; Clarithromycin; Drug Costs; Drug Therapy, Combination; Gastritis; Helicobacter Infectio | 2020 |
Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; F | 2019 |
Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cyto | 2014 |
Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy.
Topics: Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; | 2014 |
Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combina | 2015 |
Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Ciprofloxacin; Clarithromycin; Drug Therapy, Combination; Fema | 2015 |
[Effect of Helicobacter pylori eradication on patients with functional dyspepsia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2008 |
Rabeprazole combined with hydrotalcite is effective for patients with bile reflux gastritis after cholecystectomy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aluminum Hydroxide; Antacids; Anti-Ulcer Agent | 2010 |
A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Chronic Disease; | 2011 |
Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Anti | 2012 |
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Analysis of Variance; Anti-Ulcer Agents; Benzi | 2003 |
Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cardiac Surgical Procedu | 2005 |
Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Biopsy; Dis | 2005 |
[Five-day rabeprazole-based triple therapy for helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Clarithromycin; Drug Administrati | 2004 |
Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2006 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Co | 2008 |
[Clinical course of Helicobacter pylori associated chronic gastritis in post-eradicational period].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Di | 2007 |
Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromy | 1998 |
Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimid | 2001 |
Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Biopsy; | 2002 |
12 other studies available for rabeprazole and Gastritis
| Article | Year |
|---|---|
Efficacy of Sucralfate-Combined Quadruple Therapy on Gastric Mucosal Injury Induced by
Topics: Amoxicillin; Animals; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; | 2020 |
Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dr | 2020 |
Gastrointestinal: Idiopathic granulomatous gastritis observed by magnifying narrow-band imaging endoscopy.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diagnosis, Differential; Drug Therapy, Combinati | 2017 |
Dissociative disorder induced by clarithromycin combined with rabeprazole in a patient with gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clarithromycin; Dissociative Disorders; Drug Therapy, Combi | 2013 |
Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).
Topics: Amoxicillin; Chronic Disease; Clarithromycin; Disease Eradication; Female; Gastritis; Helicobacter I | 2014 |
Two Cases of Chronic Gastritis with non-Helicobacter pylori Helicobacter Infection.
Topics: Amoxicillin; Clarithromycin; Endoscopy, Digestive System; Female; Gastric Mucosa; Gastritis; Helicob | 2016 |
Electrical bioimpedance gastric motility measurement based on an electrical-mechanical composite mechanism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Case-Control Studies; China; Domperidone; Dopamine A | 2012 |
Efficacy of Helicobacter pylori eradication on the chronic mucosal inflammation of the remnant stomach after distal gastrectomy for early gastric cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer | 2005 |
Severe bradycardia in a stroke patient caused by a single low dose of escitalopram.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antidepressive Agents, Second-Generation | 2007 |
[The clinical effectiveness of rabeprazole in patients with acid-related gastric and duodenal diseases with various sensitivity of different types of parietal gastric cell receptors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Female; Gastric Acid; Gastric Aci | 2007 |
Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cell Division; Clarithromycin; Dose-Respons | 2001 |
Helicobacter pylori eradication: do we have another ace up our sleeve?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Anti-Infective Agents; Be | 2001 |